Human Small Airway Epithelial Cells and Specialized Media added to Lung Cell Portfolio
SAN DIEGO, Mar 1, 2017 -- To further support life science research and pharmaceutical drug discovery for crippling pulmonary diseases, Cell Applications, Inc. has expanded its lung cell portfolio with the addition of Human Small Airway Epithelial Cells and optimized Growth Media. HSAEpC play important roles in gas exchange, immune response and barrier function. The human small epithelium forms a continuous lining in the airways, providing a first line host defense against inhaled pathogens. In the lab, HSAEpC also provide insights to treat respiratory infection, bronchiolitis, asthma, COPD, cystic fibrosis, pulmonary hypertension and lung cancer.
Decades of studies have recently paved the way to emerging, innovative, cell-based approaches. Accordingly, HSAEpC find increasing applications for high-throughput assays, in the hope to identify new therapeutic options to treat or prevent airway disorders. Such tests included compound screening, toxicology, drug uptake and response curves. Published formats range from standard 2D 96-Well plate assays to 3D tissue models, lung organoids and airway-on-a-chip technology.
HSAEpC join an Airway System product group of primary Endothelial, Epithelial, Smooth Muscle and Fibroblast cells from tissues including Bronchial, Lung, Pulmonary, Tracheal, Microvascular and Arterial. HSAEpC are available cryopreserved, in convenient Kits containing frozen cells plus media and subculture reagents, or as fresh proliferating cells in flasks or plates.
Press & Media Relations
Daniel Schroen, PhD
VP, Sales & Marketing